4.65 USD
↘ 0.10 (2.11%)AT CLOSE (11:59 AM EDT)
Kalaris Therapeutics, Inc. Common Stock
KLRSNASDAQ • USD
4.68
↗ 0.02 (0.54%)
POST MARKET (AS OF 04:10 PM EDT)
Post Market
AS OF 04:10 PM EDT
4.68
↗ 0.02 (0.54%)
Market: CLOSED
Kalaris Therapeutics, Inc. Common Stock (KLRS) trades at $4.73 per share. The technical outlook is "Neutral" and the fundamental picture shows "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Jul 6, 2026.
Open?$4.76
High?$4.91
Low?$4.57
Prev. Close?$4.75
Volume?49.7K
Avg. Volume?81.1K
VWAP?$4.75
Rel. Volume?0.61x
Bid / Ask
Bid?$3.51 × 100
Ask?$5.00 × 200
Spread?$1.49
Midpoint?$4.26
Valuation & Ratios
Market Cap?110.6M
Shares Out?23.8M
Float?5.6M
Float %?23.6%
P/E Ratio?N/A
P/B Ratio?1.61
EPS?-$1.85
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Employees
20
Market Cap
113.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2025-03-19
Address
400 CONNELL DRIVE
BERKELEY HEIGHTS, NJ 07922
Phone: 650-249-2727
BERKELEY HEIGHTS, NJ 07922
Phone: 650-249-2727
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?1
Momentum?50
Short Sent.?28
Piotroski F-Score?0/9Weak
Altman Z-Score?-0.98Distress
Confidence?48%Low
Short InterestVery High
Short % of Float?13.61%High
Short Interest?762.7K
Days to Cover?10.9
Free Float5.6M
Avg Daily Volume69.9K
Settlement Date2026-06-15
Financial Health
Current Ratio?12.19Strong
Quick Ratio?12.19Strong
Cash Ratio?4.26Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.61CHEAP▾
Peers100
S&P84
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-1.6CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-64.3%WEAK▾
S&P3
ROA?-40.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-42710000
Enterprise Value?$76.2M
Fundamentals ratios updated end of day